PDE4B Inhibitors
1 drugsAbout PDE4B
Phosphodiesterase 4B (PDE4B) is an enzyme that regulates intracellular levels of cyclic adenosine monophosphate (cAMP), a second messenger involved in various cellular processes. By breaking down cAMP, PDE4B influences signaling pathways implicated in a range of physiological functions.
Currently, there is no genetic evidence directly linking PDE4B to specific diseases. However, its involvement in inflammatory processes makes it a compelling drug target, particularly in the respiratory therapeutic area.
There is one FDA-approved drug, Jascayd, that targets PDE4B. Jascayd, a small molecule from Boehringer Ingelheim, was first approved in 2025 for respiratory indications.
Top PDE4B Drugs
Boehringer Ingelheim is the only company with an approved drug targeting PDE4B.
Low competition suggests an opportunity for new entrants, but also highlights potential challenges.
PDE4B Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets PDE4B, using small molecule modality.
Exploring alternative modalities like antibodies could provide differentiation in the market.
PDE4B Clinical Trials 15 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on PDE4B. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 5 | 5 | 0 | 0 | 100% |
| Phase 2 | 2 | 0 | 0 | 2 | - |
| Phase 3 | 7 | 0 | 0 | 7 | - |
| Phase 4 | 1 | 0 | 0 | 1 | - |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
5 Phase 3 trials testing approved PDE4B drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting PDE4B. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
PDE4B Drug Approval Timeline (2025 - 2025)
The first and only drug targeting PDE4B, Jascayd, was approved in 2025.
Recent approval suggests a growing interest in PDE4B, but market saturation is not yet a concern.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 4 (2 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on PDE4B. A trial counts if an approved drug acting on PDE4B is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.